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1. Introduction   
Traditional Chinese medicine (TCM) possesses a rich and ancient history, tracing its roots 
back several thousand years. The practice of TCM, highly influenced by the development of 
Chinese culture, involves physical therapy using acupuncture, moxibustion (application of 
heat to the acupuncture point by burning a piece of the Chinese plant Artemisia moxa on 
the skin or the acupuncture needle), and chemical therapy. TCM natural products are 
isolated as decoctions of animal, mineral and herbal materials (Chan, 1995; Shibata, 1985;). 
The objective of the system of TCM is on the patient rather than disease, which 
fundamentally intention to promote health and enhance the quality of life, with therapeutic 
strategies for treatment of specific disease or symptoms in holistic fashion. TCM represents 
an old Chinese philosophical thinking, where the human is considered the centre of the 
universe and acts as an antenna between celestial and earthly elements of the world. The 
world is a single unit and its movement affords yin and yang, the two main antithetic 
aspects. Moreover, Chinese believe that yin and yang are not absolute but relative. 
Consistent with the modern view of homeostasis, yin and yang are interchanged to meet the 
view that yang decline and yin rises? Or yang is raised to produce a decline of yin? The four 
bodily humors (qi, blood, moitsture and essence) and internal organ systems (zang fu) play 
an important role in balancing the yin and yang in human body. Proper formation, 
maintenance and circulation of these energies are essential for health. When the two 
energies fall out of harmony, and the balance is broken, disease develops (Patwardhan et al., 
2005). The physician takes into account this concept while treating patients. Drugs or herbs 
are used to correct this imbalance of yin-yang in the human body (Cheng, 2000; Gibert, 
1998).  
Different from TCM, western science and medicine are focused on the mechanism, which 
belongs to reductionism. Rather than addressing the overall well being of a patient, it is only 
the disease that is analyzed at the cellular, molecular, and pharmacological level. The 
history, philosophy, theory and practice of TCM can been seen in recent reviews (Liu, 1988), 
herein, we do not give unnecessary details. 
Although medicinal herbs have played an important role in Western medicine from ancient 
to modern times, medicinal plants gradually lost their importance as synthetic 
pharmaceuticals advanced in Western countries during the 20th century. Currently, there is a 
revival of interest in bioactive natural products as chemical lead compounds for the 
generation of semi-synthetic derivatives, namely regression nature. 
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Traditional Chinese medicine (TCM) has held, and still holds, an important position in 
primary health care over vast rural areas of China and is appreciated in urban and well-
developed areas because of its 5000-year-old tradition. Recently, the Chinese government 
has undertaken enormous efforts to modernize TCM by investing capital in scientific 
research, technology programs, and in the economic development of TCM therapies. In the 
Western world, interest in TCM is increasing due to the belief that it may lead to novel 
TCM-Western hybrid medicines and treatments. 
Since the discovery of cisplatin (1, Fig. 1) in 1969, great progress has been made expanding 
the diversity of platinum anticancer drugs and the conditions they treat (Alt et al., 2007; 
Clark et al., 1999; Giandomenico, 1999; Jung & Lippard, 2007; Orvig & Abrams, 1999; 
Rosenberg et al., 1969; Wataru et al., 2008; Wong & Jamieson & Lippard, 1999; Zutphen & 
Reedijk, 2005). Cisplatin is currently used to treat bladder, non-small cell lung, head and 
neck, ovarian, cervical, and other cancers, being curative in nearly all cases of testicular 
cancers. Several similar platinum complexes with fewer toxic side effects, carboplatin (2, 
Fig.1 ) and oxaliplatin (3, Fig.1) were approved as a first-line treatment for colorectal cancer. 
Nedaplatin (4, Fig. 1) was approved for use in Japan, and lobaplatin (5, Fig.1) was approved 
for use in China (Lovejoy & Lippard, 2009). During the past three decades, medicinal 
chemists have investigated many approaches to enhance antitumor activity, reduce side 
effects, and overcome drug resistances. To data, thousands of platinum compounds have 
been synthesized, characterized, and their antitumor activity investigated; however, only 30 
platinum compounds have entered clinical trials. Moreover, none have exceeded the 
anticancer activity of cisplatin. Obviously, current synthetic strategies for development of 
metal-based anticancer are inefficient (Kelland, 2007). Although non-platinum antitumor 
metal complexes exhibit different action mechanisms and structural characteristics 
compared to platinum drugs, the antitumor activity of these non-platinum compounds 
needs to be determined and their action mechanisms await further investigation. Recent 
research has shown that metal complexes based on TCMs afforded a novel approach to a 
potential (pro-) drugs (Chen et al., 2009; Ho et al., 2001; Liu et al., 2009). 
 
 
Fig. 1. Strucutres of platinum compounds currently in clinical use. 1: cisplatin,  
2: carboplatin, 3: oxaliplatin, 4: nedaplatin, 5: lobaplatin. 
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2. The anticancer metal-based agents based on TCM active ingredients 
Considering the low success rate of current metal-based anticancer synthetic strategies, 
some bioinorganic chemists have shifted focus to TCM derivatives. There are many 
successful examples of TCM-derived anticancer agents through organic modification of the 
active TCM constituents, which is considered a shortcut to discover new anticancer drugs, 
however, the TCM-metal based anticancer agents are still lack of enough attention, which 
represent another approach of modification. It is well known that metals and metal 
complexes can make significant contributions to drug development, but are not receiving 
the attention they merit. Metal complexes are relative easy to prepare, and the additional 
geometric possibilities resulting from the use of six-coordinate metal centres (compared to 
four-coordinate carbon) make this an attractive approach for the rapid development of new 
species, either as drugs or as probes of the geometric requirements of active sites (Hambley, 
2007). Along with the TCM coordination chemistry theory springs up, it is convinced of that 
metal ion existence plays important role in TCM. Moreover, due to many active compounds 
containing hydroxyl, carboxylic acid, and amine groups, they are excellent donor atoms that 
may easily form coordination bonds. Developing TCM coordination complexes may lead to 
novel therapies that synergistically combine the functions of TCM and metals, generating a 
novel strategy that bridges traditional Chinese medicine to rational cancer therapy. This 
concept has attracted increased interest in TCM-metal based antitumor agents. Herein, we 
review the progress in TCM-metal based anticancer agents according to the TCM active 
gradient category. 
2.1 Alkaloid-metal based anticancer agents 
Alkaloids, which are generally defined as nitrogen-containing natural molecules 
independently of the basic character of the nitrogen, are abundant secondary metabolites in 
plants and represent one of the most widespread class of compounds endowed with 
multiple, varied pharmacological properties, including anticancer, antibacterial, anti-fungi, 
and even anti-virus activities. Up to now, the alkaloid-metal based anticancer agents mainly 
include oxoaporphine, matrine, -carboline alkaloid-metal based anticancer agents. 
2.1.1 Liriodenine-metal based anticancer agents 
Among alkaloids, the aporphinoids constitute a broad subgroup of benzylisoquinoline 
compounds, with more than 500 alkaloids isolated up to now. They are widely distributed 
in a large number of plant families including Annonaceae, Magnoliaceae, Monimiaceae, 
Menispermaceae, Hernandiaceae, Renunculaceae. Our group has widely carried out a series of 
investigations on oxoaporphine-metal based anticancer agents. Liriodenine (6, Fig. 2), as an 
oxoaporphine alkaloid, was isolated for the first time form Liriodendron tulipifera L. and 
was subsequently found mainly in the family of Annonaceae, Rutaceae, Magnoliaceae, 
Monimiaceae, Menispermaceae, ect. (Bentley, 2001; Lan et al., 2003; Lin et al., 1994; Hsien et al., 
2005; Nissanka et al., 2001; Woo et al., 1997; Wu et al., 1990). Liriodenine has a wide range of 
pharmacological activities, such as anti-bacterial, anti-fungi, antitumour and even anti-virus 
activities. Due to its planar aromatic structure, liriodenine can intercalate into the 
neighbouring base pairs of DNA double helix, to which its significant antitumor activity can 
be primarily attributed. Moreover, it also catalytically inhibits topoisomerase to block DNA 
synthesis and increase p53 and iNOS expression to induce cell cycle G1 arrest (Chang et al, 
2004). Liriodenine has been isolated by our group from a classical Chinese herb richly yield 
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in Guangxi Province of China, Zanthoxylum nitidum Var. Fastuosum, known for its significant 
anticancer properties. Based on the planar character of liriodenine and its N-7/O-8 donor 
sites, it can ligate metal ions (Mn+) to form metal-based bifunctional compounds with 
potential synergistic effects on antitumor activity. 
 
 
6 
Fig. 2. Structure of liriodenine. 
Reaction of liriodenine (L) with Pt(II), Ru(II), Mn(II), Fe(II), and Zn(II) as well as a series of 
lanthanides afforded a series of metal complexes. The crystal structures of cis-
[Pt(L)(DMSO)Cl2] (7), cis-[Ru(L)(DMSO)Cl2]1.5H2O (8) (Chen et al., 2009); [MnCl2(L)2] (9), 
[FeCl2(L)2] (10), [Zn2(L)2(2-Cl)2Cl2] (11) (Fig.3) (Liu et al., 2009); [Ce(L)2(NO3)3] (12), 
[Pr(L)2(NO3)3] (13), [Sm(L)2(NO3)3] (14), [Eu(L)2(NO3)3] (15) (Fig. 4) (Chen et al., 2011), were 
determined by single crystal X-ray diffraction methods. These complexes were fully 
characterized by elemental analysis, IR, 1H and 13C NMR spectroscopy, and ESI-MS 
spectrometry.  
 
 
Fig. 3. Crystal structures of cis-[PtCl2(L)(DMSO)] (7), cis-[RuCl2(L)(DMSO)2] (8), MnCl2(L)2] 
(9), [FeCl2(L)2] (10), and [Zn2(L)2(2-Cl)2Cl2] (11). 
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Fig. 4. Structures of four lanthanide complexes (12 to 15) with liriodenine. 
The in vitro cytotoxicity of L and a series of its metal complexes against a panel of tumour 
cell lines have been evaluated by MTT method. The results show that these liriodenine 
metal-based compounds exhibit enhanced cytotoxicity vs. free L in most cases, and the IC50 
values are in range of M, suggesting that these compounds display synergic effect in the 
combination of metal ions and liriodenine. Although there is some evidence to suggest that 
other biological targets, including RNA or proteins, may be important in the cisplatin action 
mechanism, it is generally accepted that DNA is the primary target. Similarly, interactions 
between small molecules and DNA rank among the primary action mechanisms of 
anticancer activity. DNA replication in tumour cells will be blocked by the small molecule 
intercalation of the neighboring base pairs of DNA. On the other hand, topoisomerases are 
ubiquitous molecules that relieve the torsional stress in the DNA helix generated as a result 
of replication, transcription, and other nuclear processes; they are also specific targets for a 
number of anticancer agents (Baraldi et al., 2004), including the camptothecins, 
indolocarbazoles, and indenoisoquinolines. These compounds bind to a transient 
topoisomerase I (TOPO I)-DNA covalent complex and inhibit the resealing of a single-starnd 
nick that the enzyme creates to relieve superhelical tension in duplex DNA (Holfalnd et al, 
2000; Staker et al., 2005). Therefore, in our researches, we investigated the interactions of 
these compounds with DNA and TOPO I. The interactions between ct-DNA and L or its 
Pt(II) and Ru(II) complexes through UV-Vis, fluorescence, EB competition binding, CD 
spectra, viscosity and agarose gel electrophoretic experiments reveal that these compounds 
mostly adopted a classical intercalation mode with DNA, but the metal complexes may bind 
covalently to DNA simultaneously because they easily hydrolyze to give coordinate active 
sites. Based on quantitative analysis of spectral titration experiments, it can conclude that 
the Pt(II) and Ru(II) complexes have higher binding ability than L itself does, suggesting 
that the metal complexes of planar L reinforce the binding ability. Although these results do 
not display a good coherence with what has been revealed in quantitative spectral analysis, 
however, it still confirms that DNA is an important target in cellular systems for these 
metal-based compounds derived from TCM. To introduce a TCM as a ligand to form 
bifunctional metal-based anticancer compounds (Herein, bifunction means TCM moiety 
intercalation and complex covalent binding to DNA, and differs from the meaning 
appearing in previous literature (Song et al., 2002; Wu et al., 2005) is a new effective strategy 
to achieve promising potential metal-based anticancer drug. 
The in vitro cytotoxicity of three divalent transition metal (Mn(II), Fe(II), Zn(II)) complexes 
against 10 human tumor cell lines shows that most of these metal complexes exhibit higher 
cytotoxicity than L or cisplatin does, suggesting a probable synergistic effect upon 
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liriodenine (L) coordinated to metal ions. The interactions between ct-DNA and L or its four 
divalent later transition metal complexes studied by UV-Vis, fluorescence, EB competition 
binding and CD spectra, as well as viscosity measurements and gel mobility shift assay 
experiments, reveal that these compounds mostly adopted an intercalation mode with DNA. 
Complexes 9, 10 have higher binding affinity than L itself, suggesting that the metal 
complexes of planar L reinforce the binding ability. But it is lower than that of typical 
metallointercalator, which could be attributed to dichloride complex species (neutral) 
without chloride ligand exchange for water in short incubation period. In contrast, for 
biological assay on tumor cell lines, the long period incubation could allow (inside the cell) 
the conversion to diaqua species (dicationic) with a better interaction with NDA, and exhibit 
satisfied cytotoxicity. The electrostatic interactions between complex 11 and the polyanionic 
backbone of DNA helix should be considered simultaneously. Complex 11 tends to 
hydrolyze to form coordination unsaturated species, [Zn(L)]2+, which can covalently bound 
to DNA. In addition, complexes 911 exhibit significant topoisomerase I inhibition ability at 
lower concentrations in contrast to L, implying topoisomerase I may be another molecular 
target. Although the exact molecular mechanism (including the real complex species in these 
metal complexes interacting with ct-DNA and tumour cell lines) needs further more 
detailed investigation, anyway, the three synthesized divalent later transition metal 
complexes of liriodenine exhibit significant enhanced cytotoxicity, offering a new effective 
strategy to achieve promising potential dual targeting cytotoxic agents by combining 
bioactive non-cytotoxic metal ions with cytotoxic active components from TCM. 
The in vitro cytotoxicity of the lanthanide complexes 1215 of liriodenine against four 
selected cell lines (7702, SK-OV-3, 7404, NCI-H460) were tested using MTT colorimetric 
method. The results indicate that the metal complexes exhibit enhanced cytotocicity against 
the four selected cell lines than that of liriodenine, which display the synergistic effects. All 
the complexes exhibit higher cytotoxicity to the tested tumor cells than ligand and cisplatin 
does. Remarkably, among these complexes, complexes 13 and 14 exhibit the highest 
cytotoxicity to tumour cells SK-OV-3, with IC50 values of 0.22±0.09 and 0.23±0.05 µM. The 
interactions between the liriodenine, its complexes and DNA were investigated by using 
various spectroscopic methods such as UV-Vis, fluorescence, CD, as well as viscosity and 
agarose gel electrophoresis experiments. The results indicate that liriodenine and its metal 
complexes interacted with DNA in an intercalation binding mode due to the liriodenine 
having good planarity and the  cyclic conjugated system. DNA has negative charge, there 
exist electrostatic interactions between liriodenine, its complexes. The interaction of 
complexes and DNA are stronger than that of liriodenine, it is agreed well with the results 
of antitumor activity tests. Overall, these liriodenine-metal complexes interact with DNA 
mainly by intercalation and electrostatic interaction, which blocks DNA synthesis and 
replication and induces cytotoxicity. 
2.1.2 Oxoglaucine-metal based anticancer agents 
Oxoglaucine (OG, 16, Fig. 5) is an oxoaporphine alkaloid that has been isolated from 
overground parts of plants belonging to different families such as Annonaceae (Chang et al., 
1998; Chen et al., 1996), Lauraceae (Chen et al., 1998), Magnoliaceae (Chen et al., 1976), 
Fumariaceae (Blanco et al., 1993; Tojo et al., 1991), Menispermaceae (Ohiri et al., 1982) and 
Papveraceae (Sari, 1999), which is also found widely exist in many traditional Chinese 
medicine, such as aquilegia ecalcarata Maxim (Ranunculaceae) mainly distributed in Sichuan 
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and Yunnan Provinces of China and used for the treatment of necrotic boils, pustulosis and 
other infections (Wu et al., 1998). The primary screening results reveal that oxoglaucine 
possesses strong anticancer activity, such as against HCT-8 (ED50 = 1.00 µg/ml) and KB 
(ED50 =  2.00 µg/ml) (Chang et al., 2002; Chen et al., 2002; Wu et al., 1989). In addition, 
oxoglaucine exhibits other important pharmacological activities including antiplatelet 
aggregation (Chang et al., 1998; Jantan et al., 2006), immunomodulatory activity (Ivanovska 
et al., 1997 and 2000), treatment of adjuvant arthritis (Ivanovska & Hristova, 2000), anti-
inflammatory (Remichkova et al., 2009), antifungal activity (Clark et al., 1987). 
 
 
16 
Fig. 5. Structure of oxoglaucine (16). 
 
 
Fig. 6. Structures of [OGH][AuCl4] (17), [Zn(OG)2(H2O)2](NO3)2 (18), 
[Mn(OG)2(H2O)2](ClO4)2 (19), [Mn(OG)2(H2O)2](ClO4)2 (20). 
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Oxoglaucine alkaloid (OG) was synthesized via a two-step reaction route. Using OG as 
ligand to react with corresponding transition metal salts gave rise to four metal-based 
compounds: [OGH][AuCl4]·DMSO (17), [Zn(OG)2(H2O)2](NO3)2 (18), 
[Mn(OG)2(H2O)2](ClO4)2 (19), [Co(OG)2(H2O)2](ClO4)2 (20, Fig. 6), whose structures were 
determined by X-ray single crystal diffraction analysis. The in vitro cytotoxicity of 1720 
against various tumour cell lines was assayed by MTT method. The results show that most 
of these metal-based compounds of oxoglaucine exhibit enhanced cytotoxicity vs. 
oxoglaucine and corresponding metal salts, with IC50 values ranging from 1.4 to 32.7 M for 
sensitive cancer cells, implying a positive synergistic effect. Moreover, these complexes seem 
to be selectively active against certain cell lines. The interactions of oxoglaucine and its 
metal complexes with DNA and topoisomerase I were investigated by spectroscopic, 
viscosity and agarose gel electrophoresis measurements, which indicate that these OG 
metal–based compounds interact with DNA mainly via intercalation mode. Of special note, 
these metal-based compounds effectively inhibit Topoisomerase I even at low concentration, 
implying topoisomerase I may be another molecular target. However, the exact molecular 
mechanism requires further detailed investigation. Cell-cycle analysis revealed that these 
OG-metal complexes cause S-phase cell arrest. 
2.1.3 Matrine-metal based anticancer agents 
Matrine, a quinolizidine alkaloid matrine (MT), a main component found in roots of the 
Chinese herb Sophora including Sophora flavescens and Sophora tonkinensis, was selected as an 
active ligand. Matrine has been extensively used in China for the treatment of viral hepatitis 
and cardiac diseases (Liu et al., 2007). Matrine also exhibits inhibition activity toward many 
tumour cells (such as HeLa cell and gastric cancer MKN45 cell) (Galasso et al., 2006; Luo et 
al., 2007; Ruan et al., 2006; Zhang et al., 2001 & 2007).  
Three TCM-metal compounds of Ga(III), Au(III), with Sn(IV) and matrine (MT), [H-
MT][GaCl4] (21), [H-MT][AuCl4] (22) and [SnCl5(H-MT)] (23, Fig. 7), have been 
synthesized and characterized. The crystal structure analyses reveal that 21 and 22 are 
ionic compounds, while 23 is a coordination compound formed by monodentate MT via 
its carbonyl O (Fig.7). But the ESI-MS results show that they may exist with ionic species: 
[H-MT]+, [GaCl4]-, [AuCl4]- and [SnCl5]- in water solution. The in vitro cytotoxicities of 21, 
22 and 23 against eight selected human tumour cell lines are different. In some case, they 
exhibit significant enhanced antitumour activity, such as 21 to SW480, 22 to HeLa, HepG2 
and MCF-7, which exceed matrine and cisplatin, and display synergistic contribution of 
their components. However, in the case of 23, such synergistic effect could not be 
observed due to the electronic structure alteration of lactam group of matrinium, thus 23 
exhibits lower antitumour activity than that of compounds 21 and 22. Although the 
spectroscopic and agarose gel electrophoresis assay show that these compounds bind to 
DNA inducing only small structural changes in the duplex, it could lead to a different 
cellular response. The cell cycle analyses show that compounds 21, 23 and MT exhibit cell 
cycle arrest at the G2/M phase. Their interactions with ct-DNA indicate that these metal-
matrine compounds may be act mainly via intercalation mode of H-MT. In addition, 21 
and 22 exhibit potent TOPO I inhibition ability, implying topoisomerase I may be another 
molecular target. However, the exact molecular mechanism requires further detailed 
investigation (Chen et al., 2011). 
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Fig. 7. Structures of [H-MT][GaCl4] (21), [H-MT][AuCl4] (22) and [SnCl5(H-MT)] (23). 
2.1.4 -Carboline alkaloid-metal based anticancer agents 
-Carboline alkaloids, naturally occurring nitrogen-containing ligands, for example, 
harmaline (4,9-dihydro-7-methyl-3H-pyrido[3,4-b]indole), harmalol (4,9-dihydro-1-methyl-
3H-pyrido[3,4-b] indole-7-ol), harmine (7-methoxy-1-methyl-9H-pyrido[3,4-b]indole), and 
harmane (1-methyl-9H-pyrido[3,4-b]indole), are extremely effective as antituberculosis, 
analgesic, and antimicrobial agents. Al-Allaf and co-worker reported the synthesis and 
cytotoxic evaluation of a series of novel biologically active platinum(II) (24, 26, 28, 30) and 
palladium(II) (25, 27, 29, 31, 32, Fig. 8) complex of some -carboline alkaloids (harmaline, 
harmine, and harmane). These complexes exhibited promising antitumour activity. The IC50 
of the complexes varied from 0.2 to 2.0 g/mL in the antiproliferative assays against three 
tumour cell lines, and the calculated therapeutic index varied again from 10 to 20 g/mL 
(Al-Allaf et al., 1990; Al-Allaf & Rashan, 1998). 
 
 
Fig. 8. Structures of -carboline alkaloid-metal complexes (24-32). 
2.2 Flavonoid-metal based anticancer agents 
Flavonoids are found in many plants and belong to a group of natural substances occurring 
in TCM with variable phenolic structures. Their therapeutic effects were known long before 
they were isolated (Nijveldt et al., 2001). Flavonoids display many important biological 
effects including antitumour, antioxidative, anti-inflammatory (inhibition of cyclooxygenase 
and lipoxygenase), antiviral, antibacterial, and antifungal actions. They also were shown to 
be effective inhibitors of platelet aggregation (Narayana et al., 2001; Nijhoff et al., 1995).  
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2.2.1 Chrysin, morin-metal based anticancer agents 
Chrysin (5, 7-di-OH-flavone) is one flavonoid occurring in TCM, a natural ligand for 
benzodiazepine receptors with anticonvulsant properties. Complexes with Co(II), Ni(II), 
Cu(II), Pb(II), Fe(III) and Y(III) etc., have been synthesized and characterized. [Ansari, 2008; 
Engelmann et al., 2005; Pusz et al., 1997, 2000] Recently, Tang et al. reported chrysin-La(III) 
complex, La(chrysin)2(OAc)7H2O (33, Fig. 9), which exhibited high inhibition rate (in vitro) 
to A549 and P388 with 74.5% and 42.4 at 10M, respectively; and higher too much than that 
of chrysin (4.9% and 16.7%). The intrinsic binding constants of La(III) complex and chrysin 
are 1.29106 and 5.44 105M-1, respectively, which are considered both them bind to DNA by 
intercalation (Zeng et al., 2003).  
Morin (2', 3, 4', 5, 7-pentahydroxyflavone) occurs in TCM and has antitumour activity 
(Alldrick et al., 1986). Wang et al. synthesized and characterized two complexes, 
Zn(morin)23H2O (34, Fig. 9) and Cu(morin)22H2O (35, Fig. 9) The two complexes exhibit 
higher in vitro antitumour activity to Hep-2, BBHK-2, BHK21 and HL-60 than morin alone, 
but the antitumour activity of the cobalt(II) complex (36, Fig. 9) is lower than morin (Zhang 
et al., 1996). Song and co-worker investigated the Zn(II) and Co(II) complexes of morin 
bound to ct-DNA by spectroscopic and voltammetric methods. The results indicate that they 
have different spectral characteristics and electrochemical behaviour, which suggests that 
the mode and affinity of Zn(II) and Co(II) complexes of morin bound to ct-DNA, may be 
responsible to their different antitumor activity (Song et al., 2003). 
 
 
Fig. 9. Structure of La(chrysin)2(OAc)7H2O (33) and the possible structure of the complexes. 
M = Zn(II) (34), Cu(II) (35), Co(II) (36), n = 0, or 1. 
2.2.2 Hesperetin, naringenin, and apigenin-metal based anticancer agents 
Hesperetin (5, 7, 3-trihydroxy-4-methoxy-flavanone), naringenin (4, 5, 7-trihydroxyflavanone) 
and apigenin (4, 5, 7-trihydroxyflavone), are biologically active flavonoids, commonly found in 
TCM (Tripoli et al., 2007). They have been reported to exhibit antitumour effects against breast 
cancer and hepatoma HepG2 cell lines (Korkina & Afanasev, 1997; Pereira et al., 2007). In 
addition, some metal complexes of hesperetin and naringenin have been found to exhibit 
antioxidant and anticancer activity (Chiang et al., 2006; So et al., 1996). The Naringenin Schiff 
base La(III) complex is more potent against the A-549 cell line than cisplatin under reasonable 
experimental concentrations (Li et al., 2008; Wang et al., 2006). Copper(II) complex of 
naringenin Schiff base possesses potent antioxidant activity, better than standard antioxidants 
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like vitamin C and mannitol (Li et al., 2007). Our group reported three new copper(II) 
complexes of hesperetin, naringenin, and apigenin of general composition [CuL2(H2O)2]nH2O 
(3739, Fig. 10). The in vitro antitumor activity of the copper(II) complexes vs free ligand 
against human cancer cell lines HepG-2, SGC-7901, and HeLa have been assayed. Hesperetin-
Cu(II) and apigenin-Cu(II) complexes were found to exhibit growth inhibition of SGC-7901 
and HepG2 cell lines with respect to the free ligands; the inhibitory rate of hesperetin-Cu(II) 
complex is 43.2% and 43.8%, while apigenin-Cu(II) complex is 46% and 36%, respectively. Both 
hesperetin-Cu(II) complex and hesperetin were found to bind DNA in intercalation modes, 
and the binding affinity of the complex was stronger than that of free hesperetin (Tan et al., 
2009). 
 
 
Fig. 10. The possible structure of the hesperetin-Cu(II) (37), naringenin-Cu(II) (38) and 
apigenin-Cu(II) (39) complexes.  
2.2.3 Quercetin-metal based anticancer agents 
Quercetin (3, 5, 7, 3’, 4’-pentahydroxyflavone), a widely occurring compound in TCM, 
protects DNA from damage induced by reactive oxygen species (ROS) (Russo et al., 2000). 
Quercetin can chelate metal ions to form metal complexes that have better antioxidation and 
antitumour activity than quercetin alone (Zhou et al., 2001). Williams and co-worker 
reported the synthesis, characterization, antitumoural and osteogenic activities of quercetin 
vanadyl(IV) complexes. It was found that the free ligand quercetin might be a good 
candidate to be further evaluated in the treatment of bone tissue tumours because its effect 
has been more deleterious for tumoural osteoblasts that for the normal cells. However, the 
complexation of quercetin with vanadium center does not improve its potential 
anticarcinogenic properties. On the other hand, quercetin vanadyl(IV) complex seems to be 
a promising compound because it activates type I collagen production and shows a slight 
inhibitory effect on ALP specific activity, two markers of osteoblastic differentiation. It was 
believed that the activation of ERK pathways seems to be involved at least as one possible 
mechanism in the biological effects of quercetin vanadyl(IV) complex (Ferrer et al., 2006). 
Wang et al. investigated in detail the DNA binding, cytotoxicity, apoptotic inducing activity, 
and potential molecular mechanism of quercetin zinc(II) (46, Fig. 11) and copper(II) (47, Fig. 
11) complexes. The quercetin znic(II) complex exhibits significant cytotoxicity against three 
tumour cell lines (HepG2, SMMC7721, and A549), which might be related to its intercalation 
into DNA (Tan et al., 2009). The quercetin zinc(II) complex displays strong DNA hydrolytic 
cleavage activity, which successfully promotes the cleavage of plasmid DNA, producing 
single and double DNA strand breaks, supported by evidence from free radical quenching, 
thiobarbituric acid-reactive substances (TBARS) assay, and T4 ligase ligation (Tan et al., 
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2007). Tan et al. systematically investigated the mode of DNA binding, oxidative DNA 
cleavage activity, and apoptosis-inducing activity of the quercetin copper(II) complex. The 
results showed that the antitumour mechanism of the quercetin copper(II) complex involves 
not only its oxidative DNA damage with generation of ROS but also its specific interaction 
with DNA (Tan et al., 2009). 
 
 
Fig. 11. The possible structures of quercetin metal complexes (M = Zn(II) (40), Cu(II)(41)). 
In conclusion, flavonoids possess many potential pharmacological activity, represent a large 
type of TCM ligands, but because the flavonoids contain rich phenolic and carbonyl groups, 
chelate to metal ion, very easily to form polymeric structures, resulting in poor solubility, 
that limit the actual applications. Therefore, investigation of flavonoid metal-based 
antitumour agents, the excellent synthetic and characterized techniques is required, the 
good choice of flavonoids is very important. 
2.3 Other TCM active ingredient-metal based anticancer agents 
2.3.1 Coumarin-metal based anticancer agents 
It is well documented that coumarin and a variety of coumarin derivatives have antitumour 
and antiproliferative activity. They have been shown to inhibit proliferation of particular 
human malignant cell lines in vitro, as well as affecting tumour activity against several in 
vitro tumour types (Kostova & Momekov, 2006). Kostova et al. synthesized a series of new 
zirconium(V) complexes with bis-coumarin ligands containing pyrazole or pyridine rings. 
The cytotoxic screening by MTT assay to HL-60 and the chronic myeloid leukemia LAMA-
84 indicates that the zirconium(V) complexes of coumarins proved to be less potent than the 
corresponding free ligands (Kostova & Momekov, 2006). Egan and coworker investigated in 
vitro antitumour and cytoselective effects of coumarin-3-carboxylic acid and three of its 
hydroxylated derivatives, along with their silver-based complexes using human epithelial 
carcinoma cell lines (A-498 and Hep-G2). The in vitro antitumour assay results indicated that 
all of the ligands and their silver complexes induced a concentration-dependent cytotoxic 
effect. Hydroxylation of C-3-COOH and its subsequent complexation with silver led to the 
production of a series of compounds with dramatically enhanced cytotoxicity, with 6-OH-C-
3-COO-Ag having the greatest activity, and all of the metal-based complexes were 
selectively cytotoxic to both carcinoma-derived cell lines, relative to normal renal and 
hepatic cells. The IC50 values obtained with Hep-G2 cells were between 2 and 5.5 times more 
cytotoxic than cisplatin. All of the coumarin-silver complexes inhibited the DNA synthesis, 
which did not appear to be mediated via intercalation. These findings suggest that both 
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hydroxylation, particularly in the 6th position, and complexation with silver give rise to a 
cytotoxic-selective agent that significantly targets cancer cells, relative to normal cells (Thati 
et al., 2007). In addition, Kostova and co-worker investigated the cytotoxic activity of new 
lanthanum (III) and cerium (III) complexes of bis-coumarins. Their findings suggest that the 
coumarin-lanthanide complexes exhibited cytotoxic activity in micromolar contrations. 
Their in vitro effects are clearly expressed (Kostova et al., 2005, 2006). Recently, Creaven et 
al. reported the antibacterial and anticancer activities, coordination modes of copper(II) 
complexes of Schiff based-derived coumarin ligands (Creaven et al., 2010). Therefore, these 
coumarin-metal compounds have potential to develop as anticancer drugs, which provides 
hope for the pursuit of non-platinum anticancer drugs. 
2.3.2 Cantharidin-metal based anticancer agents 
Cantharidin is the active principle of Epicanta gorhami or Mylabris(“blister beetles), which 
has long been applied as a TCM treatment for liver, lung, intestinal and digestive tract 
tumours (Wang, 1989). Cantharidin has severe side effects such as dysphagia, hematemesis, 
and dysuria (Wang, 1989). Cantharidin and its derivatives have been reported to have 
strong affinity and specificity for a protein phosphatase 2A (Li & Casida, 1992). 
Demethylcantharidin (norcantharidin, DMC) is a synthetic analogue of cantharidin and has 
potent antitumour activity but without the latter’s adverse effects (Wang, 1989). Ho and 
coworker have carried out systematic, innovative research on the combination of 
demethylcantharidin with a platinum moiety to give a series of TCM-based platinum 
compounds [Pt(C8H8O5)(NH2R)2] (42-46, Fig. 12). These platinum complexes exhibit 
selective cytotoxicity toward SK-Hep-1 (human liver cell line), and circumvention of cross-
resistance. They may possess a novel dual mechanism of antitumour action: inhibition of 
PP2A and platination of DNA (Ho et al., 2001 & 2003; To et al., 2004). Ho et al. determined 
the release of hydrolyzed demethylcantharidin from norcantharidin-Pt(II) compounds with 
anticancer activity by gas chromatography, in which the TCM component was slowly 
released from the norcantharidin-Pt(II) compounds over 24h, leading to PP2A inhibition. 
These complexes may prove to be new anticancer agents with novel mechanisms of 
cytotoxic action (To et al., 2002). The in vitro anti-proliferative activity of compounds 42-46 
was investigated in human hepatocellular carcinoma (HCC) cell lines using MTT assay, 
which showed that compounds 42-46 were approximately 2-20 and 20-200 times more 
potent than cisplatin and carboplatin, respectively, in SK-Hep1 and HepG2 cells. The in vivo 
antitumour efficacies of 42-46 were evaluated in a s.c. inoculated SK-Hep1 xenograft model 
in nude mice. Compounds 42-46 exhibited definite in vivo activity without undue toxicity, 
contrasting the lack of activity of cisplatin and carboplatin. For in vivo cisplatin resistance 
model of human HCC, compounds 42-46 performed the same level of tumour growth 
suppression as in the control tumours, indicating the circumvention of cisplatin (To et al., 
2005). Further studies indicated that compounds 42-46 were considerably less reactive to 
sulfur-containing nucleophiles than cisplatin, implying that they had reduced toxicity when 
compared with cisplatin, but the antitumour activity still remained (To et al., 2006). In order 
to determine the influence of the isomers on their anticancer activity, a series of platinum 
complexes integrating demethylcantharidin (CMC) with isomers of 1, 2-diaminocyhexane 
(DACH) have been synthesized. These compounds exhibit superior in vitro anticancer 
activity against colorectal and human hepatocellular cancer cell lines comparing with 
oxaliplatin, cisplatin, and carboplatin. The flow cytometric analysis results showed that the 
trans-DACH-Pt-DMC analogues presented similar behaviour to oxaplatin on affecting the 
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cell cycle of the HCT116 colorectal cancer cells, but different from that of cisplatin or 
carboplatin. The DACH component obviously dictates the trans-DACH-Pt-DMC complexes 
to act similar to oxaliplatin, whereas the DMC ligand enhanced the compounds’ overall 
anticancer activity. It was speculated these compounds accelerated the cell cycle from G1 to 
S-phase with subsequent onset of G2/M arrest and accompanying apoptosis (Yu et al., 
2006). Ho’s group also studied the pharmacokinetics and tissue distribution of these DMC-
Pt anticancer agents in rats. Their findings suggested that the novel DMC-Pt compounds 
might afford higher clinical efficacy and reduced systemic side effects in contrast to cisplatin 
(Wang et al., 2007). 
Moreover, the synergistic interaction between platinum-based antitumour agents and 
demethylcantharidin were investigated in vitro and in vivo, which demonstrated that 
synergistic effects occurred by combining demethylcantharidin with platinum-based 
antitumour agents. The demethylcantharidin might play a role in enhancing the efficacy of 
cisplatin in the treatment of various solid human tumours such as HCC, and overcoming 
cisplatin resistance. The demethylcantharidin has considerable promise as an adjuvant to 
chemotherapy (To et al., 2005). 
 
 
Fig. 12. Structures of [Pt(C8H8O5)(NH2R)2] (42-46) . 
The systematic work carried out by Ho’s group on cis-DMC-Pt anticancer agents provides a 
successful paradigm for future research of TCM metal-based anticancer agents by utilization 
of multi-targets and multi-mechanisms of TCM-metal based compounds. Their achievement 
make us to believe that innovative metal-based anticancer drugs enable to develop by 
integration of the multiple advantages of metals and metal complexes with TCM’s multi-
target and multi-mechanism features. 
2.3.3 Plumbagin-metal based anticancer agents 
Plumbagin (PLN) is a potent toxic natural product extracted from TCM Plumbago Zeylanica 
L. (Plumbaginaceae), which has been used in China as well as other Asian countries for the 
treatment of rheumatoid arthritis, dysmenorrhea, injury by bumping, and even cancer. The 
anticancer property of PLN against HeLa, P388 lymphocytic, leukemia, colon cancer and 
hepatoma has been reported (Aziz et al., 2008; Kuo et al., 2006; Lin et al., 2003; Olagunju et 
al., 1999; Srinivas et al., 2004). Our group carried out the studies on plumbagin metal-based 
antitumour agents. The anticancer TCM, plumbagin (PLN), was isolated from Plumbago 
Zeylanica. Reaction of plumbagin with Cu(II) salt, afforded [Cu(PLN)2]2H2O (47, Fig.13). 
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With 2,2’-bipyridine (bipy) as a co-ligand, PLN reacts with Cu(II) to give rise to 
[Cu(PLN)(bipy)(H2O)]2(NO3)24H2O (48, Fig. 13). The two complexes were characterized by 
elemental analysis, IR, and ESI-MS. Their crystal structures were determined by single 
crystal X-ray diffraction methods (Fig. 13) And the in vitro cytotoxicity of PLN and the two 
copper complexes against seven human tumour cell lines was assayed. The metal-based 
compounds exhibit enhanced cytotoxicity vs. that of PLN, suggesting that these compounds 
display synergy in the combination of metal ions with PLN. The binding properties of PLN 
and the two copper complexes to DNA were investigated with UV-vis, fluorescence, CD 
spectroscopy, and gel mobility shift assay, which indicated that the two copper complexes 
of plumbagin were non-covalently binding and mainly intercalated in the neighboring base 
pairs of DNA. PLN and its copper complexes exhibit inhibition activity to topoisomerase I 
(TOPO I), but the metal complexes were more effective than PLN (Chen et al., 2009). 
 
 
Fig. 13. Crystal structures of [Cu(PLN)2] (47) and [Cu(PLN)(bpy)(H2O)](NO3)2 (48). 
This work has recently been reviewed by Professor Roy Planalp. He thought that this work 
is very exciting with regards to the enhanced antitumour properties of a natural substance 
by complexation with a common biometal (Saxton, 2010). 
In order to investigate the cytotoxicity of plumbaginate lanthanide complexes, five new 
lanthanide(III) complexes of deprotonated plumbagin: [Y(PLN)3(H2O)2] (49), 
[La(PLN)3(H2O)2] (50), [Sm(PLN)3(H2O)2]H2O (51), [Gd(PLN)3(H2O)2] (52), and 
[Dy(PLN)3(H2O)2] (53, Fig. 14) were synthesized by the reaction of plumbagin with the 
corresponding lanthanide salts, in amounts equal to ligand/metal molar ration of 3:1. The 
PLN-lanthanide(III) complexes were characterized by different physicochemical methods: 
elemental analyses, UV-visible, IR and 1H NMR and ESI-MS as well as TGA. The plumbagin 
and its lanthanide(III) complexes 4953, were tested for their in vitro cytotoxicity against 
BEL7404 (liver cancer) cell lines by MTT assay. The five PLN-lanthanide (III) complexes 
4953 effectively inhibited BEL7404 cell lines growth with IC50 values of 11.03.5, 5.11.3, 
6.11.1, 6.41.3, and 9.81.5μM, respectively, and exhibited a significantly enhanced 
cytotoxicity compared to plumbagin and the corresponding lanthanide salts, suggesting a 
synergistic effect upon plumbagin coordination to the Ln(III) ion. The lanthanide complexes 
under investigation also exerted dose- and time-dependent cytotoxic activity. 
[La(PLN)3(H2O)2] (50) and plumbagin interact with calf thymus DNA (ct-DNA) mainly via 
intercalation mode, but for [La(PLN)3(H2O)2] (50), the electrostatic interaction should not be 
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excluded; the binding affinity of [La(PLN)3(H2O)2] (50) to DNA is stronger than that of free 
plumbagin, which may correlate with the enhanced cytotoxicity of the PLN-lanthanide(III) 
complexes (Chen et al. 2011). 
 
 
Fig. 14. The possible structure of complexes 4953 (n=0, Ln = Y(III) (49), La(III) (50), Gd(III) 
(52), Dy(III) (53); n = 1, Ln = Sm(III) (51)). 
2.3.4 Curcumin-metal based anticancer agents 
Curcumin, an extract of turmeric, Curcuma longa L., has been used for centuries in variety 
of TCM pharmaceutical applications (Sharma, 1976), including treatment of arthritis 
(Deodhar et al., 1980), as an anti-inflammatory agent (Rao et al., 1982; Srimal & Dhawan, 
1973) and as an orally available treatment for diabetes (Arun & Nalini, 2002). Thompson and 
co-worker synthesized a novel vanadyl curcumin complex (VO(cur)2) (54, Fig. 15) and 
studied its anticancer potential in inhibiting mouse lymphoma cell growth. The complex 
was more effective than uncoordinated curcumin (Thompson et al., 2004). 
 
 
Fig. 15. Structure of vanadyl curcumin complex (VO(cur)2 54). 
2.3.5 Camphorato-metal based anticancer agents 
Camphor has long been used as TCM to relieve pain, stop tickle, anti-inflammation, cure 
ulcers and sores, dental caries, and kill worms and acariasis as early as the Ming Dynasty. 
Camphoric acid can be obtained by the oxidation of camphor and is used in 
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pharmaceuticals as exciting centre and respiration analeptic agent. Gou and coworker 
synthesized eight new camphorato platinum complexes (55, Fig. 16) and evaluated their 
in vitro cytotoxicity against HL-60, 2AO, BEL-7402 and A549 cells. The results show that 
most complexes exhibited good cytotoxic activity against the selected cell lines. One 
complex displayed not only higher in vivo antitumour activity, but also less toxicity than 
oxaliplatin when it was administered intravenously at a dose of 6 mg/Kg three times. 
Gou and coworkers research provides a new selection to find chiral leaving groups from 
TCM (Wang et al., 2005). 
 
 
Fig. 16. trans-1R, 2R-Daiminocyclohexane camphorate-Pt complex (55). 
3. Conclusion 
TCM is a natural “combination chemical resources armoury”, which has undergone several 
thousands years worth of clinical practice and screening. TCM possess multi-component, 
multi-target and co-regulatory features which meet the view points of multi-target drugs 
through the network approach (Csermely et al., 2005) and robustness-based approach to 
systems-oriented drug design (Kitano, 2007). TCM metal-based antitumor agents have at 
least two remarkable advantages: either TCM playing key role or metal complex making 
multiple contributions in development of drugs. In this review, the alkaloids, flavonoids, 
cantharidin, coumarins, plumbagin, curcumin and camphoric acid metal-based compounds 
with antitumor activity were summarized. Generally, TCM-metal based compounds formed 
via metal ions coordinating to TCM with O, N donors, exhibiting enhanced activity and 
synergistic effect with multi-targets and multi-mechanisms. With the Chinese government 
promotion of the modernization of TCM (Normile, 2003) and carrying out the herbalome 
(Stone, 2008), as well as the advancements of genome, proteome, metabolome, there is the 
possibility to design new TCM metal-based anticancer drugs and develop modern TCM, 
which will benefit to overcoming multidrug resistance (MDR). The promising trends have 
been supported by great potential of TCM metal-based antitumor agents mentioned above. 
We believe that innovative metal-based anticancer drugs enable to develop by integration of 
the multiple advantages of metals and metal complexes with TCM’s multi-target and multi-
mechanism features. But the action species and multi-target and multi-mechanism in cell 
and in vivo of the TCM metal-based antitumor agents still need to be widely and deeply 
investigated by adopting modern genome, proteome, metabolome technologies.  
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During the recent years, traditional Chinese medicine (TCM) has attracted the attention of researchers all over
the world. It is looked upon not only as a bright pearl, but also a treasure house of ancient Chinese culture.
Nowadays, TCM has become a subject area with high potential and the possibility for original innovation. This
book titled Recent Advances in Theories and Practice of Chinese Medicine provides an authoritative and
cutting-edge insight into TCM research, including its basic theories, diagnostic approach, current clinical
applications, latest advances, and more. It discusses many often neglected important issues, such as the
theory of TCM property, and how to carry out TCM research in the direction of TCM property theory using
modern scientific technology. The authors of this book comprise an international group of recognized
researchers who possess abundant clinical knowledge and research background due to their years of
practicing TCM. Hopefully, this book will help our readers gain a deeper understanding of the unique
characteristics of Chinese medicine.
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